Skip to main content

Table 1 Demographics. Adult/adolescent study

From: Arbaclofen in fragile X syndrome: results of phase 3 trials

Group/characteristic

Placebo (N = 63)

Arbaclofen (N = 62)

Total (N = 125)

Mean age (SD)

18.7 (7.22)

19.0 (6.73)

18.9 (6.96)

Age group (adolescents age 12–17)

36 (57.1%)

31 (50.0%)

67 (53.6%)

Gender (males)

49 (77.8%)

50 (80.6%)

99 (79.2%)

 Race/ethnicity

   

 White non-hispanic

50 (79%)

47 (76%)

97 (77%)

 White hispanic

4 (6.5%)

5 (8.1%)

9 (7.2%)

 African American

6 (9.5%)

5 (8.1%)

11 (8.8%)

 Asian

1 (1.6%)

1 (1.6%)

2 (1.6%)

 Other

2 (3.2%)

4 (6.5%)

6 (4.8%)

Concomitant medications

   

 Any psychotropic medications

40 (63.5%)

35 (56.5%)

75 (60.0%)

 Antipsychotics

11 (17.4%)

14 (22.6%)

25 (20.0%)

 None

23 (36.5%)

27 (43.5%)

50 (40.0%)

DSM-IV diagnosis of ASD

45 (71.4%)

46 (74.2%)

91 (72.8%)

Mean ABC-CFX Social Avoidance score (SD)

7.9 (3.48)

7.6 (3.17)

Â